Background: Non-alcoholic fatty liver disease (NAFLD) is now predominant globally due to increased sedentary
associated with insulin resistance (IR) [2] . Recently, increased incidences of NAFLD were reported in nonobese or lean individuals (with normal BMI) in population of Asian origin [3, 4] . In rural India, non-obese NAFLD has been documented in patients those are neither overweight nor centrally obese [4] . Lean NAFLD also has been described from other parts of the world [5] . Lean NAFLD like obese patients also develops problematic sequels like steato-hepatitis, fibrotic disease, cirrhosis and HCC [6] .
It has also been documented that small intestinal bacterial overgrowth (SIBO), an association with NAFLD may be more prevalent among the Asians [4, 7] . The SIBO induced endotoxins, which reaches liver through portal circulation might be inducing pro-inflammatory cytokines in liver from Kupffer's cell or Hepatic Stellate Cell (HSC) or sinusoidal endothelial cells [8] . The source of proinflammatory cytokines in obese patients have been documented to be the macrophages in peripheral adipose tissues [9] which lean NAFLD patients do not possess. The hepatic milieu of non-obese NAFLD patient may be different than obese NAFLD patient and the biomarkers for severity of NAFLD can be better represented in hepatic than systemic circulation. The adipose tissue of obese patients exerts substantial systemic effect and also NAFLD severity. Progression from Non-alcoholic Fatty Liver (NAFL) to Non-alcoholic Steatohepatitis (NASH) even though unclear, is thought to be induced by secondary hits such as proinflammatory adipo-cytokines, lipotoxicity, or oxidative stress [10] . In our earlier reported pilot study, significantly high levels of IL-6 cytokine were observed among lean NAFLD patients in comparison to controls (CHB and obese NAFLD) possibly due to SIBO induced endotoxins [11] . Whether oxidative stress, antioxidants and adipokines have similar association in lean as in obese NAFLD is also not clear.
Therefore, the present study was under taken to assess differences in hepatic fat content and clinical spectrum of NAFLD by Magnetic Resonance Spectroscopy (MRS), USG, fibroscan and histopathological examination in obese and non-obese NAFLD patients. The extent of liver injury was correlated with circulatory biomarkers of oxidant stress, antioxidants, proinflammatory adipo-cytokines and endotoxin induced lipopolysaccharide binding protein (LBP) in hepatic and systemic circulation. The hepatic gene expression of LBP and proinflammatory cytokines was confirmed in transjugular liver biopsy tissue. Anthropometric parameters, insulin resistance and SIBO were compared in lean and obese NAFLD patients.
Methods

Patients and definitions
Institute ethics committee approval (IEC/NP-87/2012, RP13/2012). This prospective observational study was carried out in tertiary care setting at the Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India during November 2012 to January 2015 after obtaining institute ethics committee approval. All consecutive NAFLD patients and chronic hepatitis B (CHB) as disease control attending liver clinics were recruited as per inclusion and exclusion criteria. The included NAFLD patients of age > 18 years were initially screened by ultrasonography (USG) and confirmed by liver histology (involvement of > 5% of hepatocytes by steatosis and NASH was defined by NAS-CRN score ≥ 5) [12] . The CHB patients with minimum 1.5 times elevated ALT and without any evidence of fatty liver on histology, were included as disease controls. Healthy individuals matched for age, sex and BMI with normal liver function tests and without any evidence of fatty liver (on USG), diabetes mellitus or alcohol consumption or any other comorbid diseases, were included as healthy controls.
The exclusion criteria for patients were use of known fatty liver causing drug, anti-tuberculosis drugs and patients with diabetes mellitus, alcoholics or pregnant females. In addition, the patients with other etiologies of chronic liver disease such as hepatitis C, Wilson's disease, autoimmune liver disease, alpha 1 anti-trypsin deficiency and hemochromatosis were also excluded.
Patient evaluation and clinical investigations
The clinical, demographic and anthropometric (weight, height, waist and hip circumferences) were recorded. As per WHO recommendations, BMI cut off ≥ 25 kg/m 2 for Asian populations was considered as criteria for obesity [13] . The abdominal obesity was determined using recommended cut off for waist circumference (> 90 cm for male and > 85cm for female) and the waist hip ratio (> 0. 90 for male and > 0. 85 for female). The hepatic fat content of NAFLD and CHB patients were assessed by magnetic resonance spectroscopy [14] . Ultrasonography of abdomen and liver in NAFLD patients were carried out as per standard protocol [15] . Overnight fasting blood samples were collected for biochemical investigations. Insulin resistance (HOMA-IR) was determined by taking consideration into fasting serum insulin and fasting plasma glucoses [16] . Hypertension, Type 2 diabetes mellitus, and dyslipidemia were defined as per accepted WHO criteria [17] .
Glucose hydrogen breath test (GHBT)
For GHBT, breath hydrogen in parts per million (ppm) was estimated every 15 min for 2 hour following ingestion of 70 g glucose (dissolved in 200 ml water). An increase in breath hydrogen by at least 12 ppm above the basal level or an average value of basal breath hydrogen ≥ 20 ppm following glucose administration was considered positive for SIBO [18] .
Hepatic venous sampling and trans-jugular liver biopsies
The hepatic venous blood sampling was performed in NAFLD patients and CHB controls through trans-jugular approach [19] . The trans-jugular biopsy samples in parts were both formalin-fixed and snap frozen for histopathological examinations and assessed for hepatic gene expression.
Enzyme Linked Immunoassay (ELISA)
Detection of LBP and leptin in serum was done by sandwich ELISA; whereas detection of other adipokines (Visfatin, Resistin and Adiponectin) was carried out by competitive ELISA using commercial kit as per manufacturer's instructions (Ray biotechInc, Norcross, USA).
Oxidant and antioxidant measurement
Lipid peroxidation was assessed colorimetrically by measuring plasma malondialdehyde (MDA). Total antioxidant capacities were measured as ferric reducing ability of plasma (FRAP), by the methodology given by Benzie and Strain [20] . Superoxide dismutase (SOD) was estimated by the 50% inhibition of auto-oxidation of pyragallol at pH 8. 0 [21] . Plasma vitamin C was measured by dinitrophenyl hydrazine method [22] .
Relative gene expression
Total RNA was isolated from the liver biopsy samples by using SV Total RNA Isolation System (Promega Corporation, Madison, USA). The cDNA was prepared using Go Script Reverse transcription system (Promega Corporation, Madison, USA). Real time PCR for gene expression was carried out by using SYBR green chemistry. The primers for real time PCR were designed (Table 1 ) from NCBI reference sequences for genes such as GAPDH, ADIPONECTIN, LEPTIN, LBP, IL6, IL1B, TNFα using bioinformatics software. The relative expression of LBP, proinflammatory cytokine and adipokine genes in liver of non-obese and obese NAFLD patients as compared to CHB disease control were analyzed by comparative Ct method using GAPDH gene as endogenous normalization control.
Statistical analysis
Normally distributed continuous variables were expressed as mean ± standard deviation (SD) and categorical variables were expressed as percentages. Continuous variables were compared by student t-test or ANOVA test and categorical variables were compared by chi-square test and p value of < 0.05 was considered to be significant. Associations between variables were performed using Spearman's correlation coefficients.
Result Patient recruitment and demographic profile
Out of 140 clinically diagnosed NAFLD cases during the study period, 86 patients were excluded due to diabetes (n=13), cirrhosis (n=2), drugs (methotrexateand antitubercullosis drug, n=2) andrefusal to consent (n= 69). A total of 104 subjects were studied including 54 NAFLD patients and 50 controls (25 CHB and 25 healthy). The demographic and baseline clinical profiles of controls and patients are depicted in table 2. The BMI, waist hip ratio (WHR), LDL, serum insulin levels, HOMA-IR and ALT levels were significantly (p<0. 001) higher in NAFLD patients as compared to both control groups (Table 2) . Metabolic syndrome criteria [23] were fulfilled in 18. 51% of NAFLD patients (n=10).
Obesity among NAFLD patients
Using BMI cut off (> 25 kg/m 2 ) values, 53. 7% (29/54) were obese and rest 46. 3% (25/54) was non-obese or lean NAFLD. Abdominal obesity was documented in 72. 23% (n=39/54) and 94. 44% (n=51/54) cases of NAFLD patients on the basis of waist circumference and WHR, respectively. The BMI, waist circumference and the WHR values were significantly higher in NAFLD than in CHB as well as healthy controls (Table 2) .
Insulin resistance, hypertension and SIBO prevalence among NAFLD, CHB and healthy control
Insulin resistance (HOMA-IR> 2.5) was observed in 21/54 (38.8%) of NAFLD, 2/25 (8%) in CHB control and none in healthy control. IR was significantly correlated with obese NAFLD (p = 0.02, OR=3.57, 95% CI=1.11-11.47) as evidenced by higher proportion of IR in obese (n=15, 51.7%) than non-obese NAFLD (n=6, 24%). However, the fasting serum Insulin levels were significantly higher in both obese and non-obese NAFLD than both healthy and CHB controls ( 
Fatty liver and its severity in NAFLD patients by MRS, USG and Fibroscan
The mean liver fat content (LFC) by MRS was 20.44 ± 10.48%, 16 ± 11.52% and 9.34 ± 15.4% for obese, nonobese NAFLD and CHB patients, respectively ( Figure 1B ). Abnormal accumulation of liver fat (> 5.56% LFC) was observed equally high in significant proportion of obese (93. 34%) and non-obese (92.86%) NAFLD patients than CHB (28.5%) control ( Figure 1A ). Healthy controls were not subjected to MRS due to lack of detection of fatty liver by USG. Increasing spectrums of fatty liver grade were observed in obese (Grade I: 37.94%, II: 55.17% and III: 6.89%) than non-obese (Grade I: 64%, II: 28% and III: 8%) NAFLD patients (p = 0. 0001) by USG. N o fatty liver (Grade 0) was observed in 92% (n=23/25) and 100% (n=25/25) in CHB disease and healthy control ( Figure 1C ). In Fibroscan, higher LSM score (>7 KPa) was observed in obese (37.9%, n=11/29) than non-obese (16%, n=4/25) NAFLD patients. The fibrosis staging among groups were as follows: nonobese (F2:8% and F3:8%), obese NAFLD (F2: 13.79%, F3:24.13%) and CHB control (F2:28%, F4: 12%) (p = 0.02) ( Figure 1D ).
NAFLD severity in liver biopsy by histopathological examination
The inflammation grades which include no inflammation (NAFLD activity score, NAS < 3), mild NASH (NAS ≥ 3-4) and confirmed NASH (NAS ≥ 5) were found in 11.11% (n=6/54), 48.15% (n=26/54) and 40. 74% (n=22/54) cases respectively in NAFLD patients. The fatty liver with inflammation (mild and confirmatory NASH) were equally observed in non-obese (56%, n=14/25 and 32%, n=8/25) and obese (41.38%, n=12/29 and 48.28%, n=14/29) NAFLD patients ( Figure 1C) . In CHB controls, minimal inflammation (HAI ≥ 3-4) was 68% (n=17/25) and mild inflammation (HAI ≥ 5-8) was observed in 32% (n=8/25) of cases ( Figure 1E ).
In NAFLD patients, the stages of fibrosis as per the NASH CRN staging criteria were F0 (no fibrosis) in 29. 63% (n=16/54), F1 (mild fibrosis) in 48. 15% (n=26/54), F2 (moderate fibrosis) in 12.96% (n=7/54) and F3 (severe fibrosis) in 9.26% (n=5/54) cases. In non-obese, obese and CHB controls, F0 was 36% (n=9/25), 24.13% (n=7/29) and 32% (n=8/25) cases; F1 was 48% (n=12/25), 48.28% (n=14/29) and 44% (n=11/25) ; F2 was 4% (n=1/25), 20.68% (n=6/29) and 16% (n=4/25) ; F3 was 12% (n=3/25), 6.89% (n=2/29) and 0 cases; F4 (cirrhosis) was observed in 8% (n=2/25) CHB disease control only ( Figure 1F ).
LBP as surrogate marker for SIBO in NAFLD patient
The upper limit of normal LBP was considered 13 µg/ml based on the value of healthy control which was reported 10 μg/ml earlier [24] . Significantly higher LBP levels was observed among NAFLD groups (hepatic and Systemic: 25.93 ± 15.8 µg/ml, 24.07 ± 14.7 µg/ml in nonobese and 18.23 ± 14.90 and 17.50 ± 15.87 µg/ml in obese) than CHB (6. 91 ± 7.27 and 5. 34 ± 3.72 µg/ml) and healthy (systemic: 13.01 ± 5.49 µg/ml) control (p=0.0001). Higher prevalence of increased hepatic and systemic LBP was found in both non-obese (56%, n=14/25 and 60%, n= 15/25) and obese (41.3%, n= 12/29 and 448%,n=13/29) NAFLD group as compared to CHB (12%, n=3/25 and 0%) and healthy (systemic:20%, n=5/25) control (p = 0.009; 0.001 in hepatic and systemic). The systemic and hepatic LBP was positively correlated (r=0.826 and 0.774, p = 0.001 and 0.0001 in non-obese and obese NAFLD).
Comparison of hepatic and systemic oxidative stress, adipokine and cytokine level among groups
The MDA level in hepatic and peripheral blood was significantly (p = 0.0007) higher in NAFLD group than CHB and healthy control (Table 3) . Total antioxidants (FRAP), Vitamin C level of NAFLD and CHB control was significantly less than healthy control. The SOD level was identical among groups ( Table 3 ). The hepatic level was positively correlated with systemic level (r=0.812, 0.627, 0.8 for MDA, FRAP and Vitamin C, p=0.001). The pro-inflammatory adipokine, leptin (both hepatic and systemic) was significantly (p ≤ 0.01) higher in obese and non-obese NAFLD than CHB and healthy control (Table 4) . Lower levels of adiponectin were observed in obese and CHB groups (hepatic: 83.11 ± 74.03 µg/ml, and systemic: 64.63 ± 75.49 µg/ml) whereas equivalent levels were observed in non-obese (175.77 ± 170.52 µg/ ml) and healthy control (systemic: 173.46 ± 156.05 µg/ ml) group. Increased visfatin level was observed in nonobese NAFLD than CHB and healthy control; however equivalent levels were found in obese and control group (Table 4) . Increased level of cytokine TNF-α and IL-6 was found in both obese and non-obese group than and healthy control. Comparatively low level of IL-1b was observed among all the groups (Table 5) 
Hepatic gene expression of LBP, adipokine and cytokine among groups
The mRNA expression of LBP was up-regulated in 78.9% and 70% cases of non-obese and obese patients (Figure 2a and d) . The mRNA expression of leptin ( Figure  2b and e) was up-regulated in 68.4% and 75% cases; whereas adiponectin (Figure 2c and f) was 73.68% and 65% cases of non-obese and obese NAFLD patients, respectively. Increased expressions of pro-inflammatory cytokines were observed in 84.21% and 65% cases for IL-6 ( Figure 3a and d) ; 89. 47% and 55% cases for IL-1b ( Figure  3b and e) ; 57.89% and 45% cases for TNF-α (Figure 3c and f) in non-obese and obese NAFLD patients, respectively. 
Association of IR, SIBO and LBP with lean and obese NAFLD and its correlation
Discussion
The present study provided specific clinical patterns of NAFLD associated with WHO criteria of obesity and without so, and identified the limitations of established criteria of screening individuals for NAFLD in Indians. This study evaluated the influence of obese and nonobese conditions with hepatic fat content and extent of liver injury in Indian NAFLD patients. Whether systemic changes associated with NAFLD are similar to the events inside the liver was further confirmed in hepatic circulation and also by gene expression. The NAFLD patients were compared with diseased (CHB) and healthy controls. The study population was not derived from known high risk population of NAFLD rather obtained from consecutive non-diabetic and non-alcoholic patients incidentally detected to have fatty liver by USG with various nonspecific symptoms such as dyspepsia to mimics a real life scenario.
Out of these 54 biopsy confirmed NAFLD patients, 54% had increased BMI > 25 kg/m 2 , 72% had increased waist circumference and 94.4% had increased WHR. In Indian subjects of without T2DM or alcohol or drug history, increased WHR can be the indicators for presence of NAFLD. In the present study, all the patients with NAFLD had MRS to estimate more objectively the fat content of the liver and in about 95% of both groups of NAFLD (BMI > 25 and < 25 kg/m 2) had fat in more than 5.56% of liver tissue and 15 to 20% of the liver content were due to fat which confirmed that indeed all of them had fatty liver which was further confirmed in liver histology. The excess fat accumulation either due to obesity or abdominal obesity alone results in adipocytes hypertrophy and macrophage infiltration which disrupts normal function of adipose tissue leading to deregulation of adipokines, alteration of glucose and lipid homeostasis; and inflammatory immune responses [25] . We had observed that even with lower BMI and increased WHR, the fat content of the liver was increased. Whether, these amounts of fat are associated with increased inflammation or fibrosis and whether it can be considered as markers for disease progression need to be evaluated. For this, the patients with lower BMI and waist circumference were evaluated by histo-pathological examination. As per NASH-CRN criteria 40.74 % (n=22) of all NAFLD had NASH (NASH-CRN > 5) and 22% (n=12) had F2 and F3 fibrosis. Even though about 27.58% (n=8) of those with higher BMI (> 25 Kg/m 2 ) had F2/F3, about 16% (n=4) NAFLD with BMI<25 had F2/ F3 fibrosis. Similarly, about 32% of the later group and 49% of the former group had NASH CRN score of > 5. The results of Fibroscan were similar to liver histology in these patients. These findings together may suggest that Indians are more prone to develop NAFLD with minimal non overt weight gain and about 30% off these patients even without any risk factors for NAFLD had evidence of progressive disease in the form of overt histological NASH. Therefore, detection of NAFL by USG in these parts of the world need further evaluation to identify the high risk NASH who progresses and need the specific management.
In these patients with NAFLD (both high and low BMI groups), IR was documented and established earlier as pathogenetic driver. Release of free fatty acids (FFAs) to circulation either due to peripheral or central obesity modulates insulin sensitivity and NAFLD pathogenesis [26] . Equivalent proportions of increased triglyceride level (44% and 41.37%) and decreased HDL level (32% and 31.03%) were observed in both non-obese and obese NAFLD patients of this study. The Insulin levels in both the group were markedly and significantly higher than both the control groups ( Table 2 , P < 0. 0001). However, HOMA-IR estimation indicating IR was documented in 51.7% (n=15) and 24% (n=6) of the patients with high and low BMI respectively. In Indian patients, cut off of HOMA-IR has not been properly worked out to indicate IR which may be much lower than the present study cut off. Earlier rural population study from India [4] , reported the value of mean Insulin level as 6.83 + 3.24 and as 6.66+ 2.16 mIU/ml in both lean NAFLD the lean control (without NAFLD) group respectively. HOMA-IR in them was 1.63 + 1.65 and 1.41 + 0.39, respectively. However all the lean NAFLD group patients had mild rise in weight in the form of increased WHR. Therefore, minimal weight in Indian patients is possibly resulting central obesity and IR as indicated by higher serum Insulin levels. The present study documented additional possible pathogenetic link which might be accelerating the effect of rise of Insulin level in such patients. We documented that the frequency of SIBO in our NAFLD patients (non-obese and obese group, 4% and 17.2%) were higher than the controls. Furthermore, significantly high LBP levels (both hepatic and systemic) in NAFLD patients as compare to control was documented. These finding were further corroborated with relative expression of LBP mRNA in NAFLD liver tissues (Figure 2a and d). These finding would suggest that the gut derived liposaccharide are indeed reaching the liver and inducing LBP production in Indian patients. Increased expressions of proinflammatory adipo-cytokines like leptin, visfatin, TNF and IL6mRNA were also documented (Figures 2 and  3 ). There was a linear correlation between LBP mRNA and the cytokine mRNA. Earlier studies including our center also documented increased serum levels of MDA in obesity and NAFLD [11, 27, 28] . Dysregulation of adipokines due to hypertrophy of adipocytes or infiltration of immune cells has been implicated in inducing chronic inflammatory state in metabolic disorders [29] . The upregulation adipokines such as leptin, resistin, visfatin, retinolbinding protein 4 (RbP4), lipocalin 2 and angiopoietinlike protein 2 (ANGPTL2) induce pro-inflammatory state and down-regulation of anti-inflammatory adipokine such as adiponectin, SFRP5 also contributes to metabolic dysfunction and inflammation [30, 31] . These inflammatory adipo-cytokine, along with FFA and gut derived LPS activate inhibitory molecules such as SOCS, PTP1b and JNK to suppress insulin signaling through interaction of IRS (insulin receptor substrate) resulting in insulin resistance [32, 33] . Therefore it is possible that in Indians who develop NAFLD with minimal weight gain (so called Lean NAFLD), the disease is often progressive. SIBO and endotoxemia (evidenced by increased LBP expression in liver &increase LBP in hepatic venous and systemic blood) might be inducing upregulation of proinflammatory cytokines associated with oxidative stress (also documented among NAFLD patients in this study) may be causing liver damage in such patients.
This study has few limitations. This is an observational study from single tertiary care center in urban setting, which may be associated with a referral bias. The observations of this study for non-obese NAFLD patients are not comparable to NAFLD patients without abdominal obesity from rural setting which may have different pathogenesis. We did not use CT scan to assess the visceral and abdominal fat.
In conclusion, minimal weight gain in Indians with increased WHR (and not necessarily with increased BMI) is associated with increased liver fat accumulation, higher serum Insulin levels and progressive liver disease (fibrotic NASH and NASH CRN score > 5 in about one third of these patients). The study further documented higher frequency of SIBO in these patients than controls. The LBP expression due to gut derived LPS had shown higher level in the liver tissue, hepatic and peripheral circulation which was well correlated with increased proinflammatory cytokines in liver tissue. The hepatic and systemic levels of biomarkers were well correlated. Increased level of lipid peroxidation product and proinflammatory adipocytokines were observed in hepatic than systemic circulations. All of these factors in combination might be causing progressive liver damage in so called "Lean NAFLD".
